Product Description
Since last many years Saintroy Lifescience is leading manufacture, export and supplier of Trastuzumab for Injection from Surat, Gujarat, India. Trastuzumab for Injection used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive.
Tags: Trastuzumab for Injection manufacturer, Trastuzumab for Injection exporter, Trastuzumab for Injection supplier,and Trastuzumab for Injection, whogmp approved Trastuzumab for Injection Manufacturer and supplier, Trastuzumab for Injection distributor, Trastuzumab For Injection shipper, Trastuzumab for Injection 150 mg Trastuzumab for Injection 150 mg supplier, Trastuzumab for Injection 150 mg.
ISO/GMP/cGMP/WHOGMP/NAFDAC approved, PPB Kenya approved/USFDA approved/EUGMP approved/MOH Iran approved manufacturing facility in Gujarat, India.
Registration: Saintroy Lifescience is interested in registration of own brand or customer brands in ministry of health of clients country and we also provide the products samples, COA, COPP, ACTD or CTD dossier, DMF, Manufacturing license, Free sales certificate and other required documents.
Targeted Cancer TherapyTrastuzumab is a monoclonal antibody that specifically targets the HER2 receptor, which is overexpressed in certain types of breast and gastric cancers. By binding to this receptor, trastuzumab helps inhibit tumor growth and can improve survival outcomes when used as part of a combination therapy. This targeted mechanism makes it an essential treatment option for patients with HER2-positive cancers.
International Quality AssuranceProduced under International GMP-certified standards, Trastuzumab For Injection ensures consistent quality, efficacy, and safety for all patients. Each vial contains a precise 150 mg dose, offering reliability for healthcare providers. The manufacturing and supply chains uphold strict compliance, making the product suitable for use in regulated hospital and clinical settings.
Reconstitution and AdministrationSupplied as a white to pale yellow lyophilized powder, Trastuzumab must be reconstituted with bacteriostatic water for injection before use. Healthcare professionals then administer the medication through intravenous infusion, allowing for precise and controlled delivery. The vial is single-use, ensuring safe and hygienic dosing for every patient.
FAQ's of Trastuzumab For Injection:
Q: How should Trastuzumab For Injection be prepared and administered?
A: To prepare Trastuzumab For Injection, reconstitute the lyophilized powder with the provided bacteriostatic water for injection. The solution should be gently swirled, not shaken, to dissolve completely. After reconstitution, it is administered intravenously as an infusion by qualified healthcare professionals according to the prescribed dosage and schedule.
Q: What are the main indications for using Trastuzumab For Injection 150 mg/vial?
A: Trastuzumab For Injection is primarily indicated for the treatment of HER2-positive metastatic breast cancer, early breast cancer, and HER2-positive gastric cancer. Its use is based on the overexpression of the HER2 protein in cancer cells, allowing targeted therapy for these specific malignancies.
Q: When should the reconstituted solution be used after preparation?
A: The reconstituted solution should be used as soon as possible after preparation. Follow the specific guidance provided by healthcare professionals or the manufacturer for any maximum allowable storage period after reconstitution, as product stability may be affected over time.
Q: Where should Trastuzumab For Injection be stored before and after reconstitution?
A: Prior to reconstitution, the vial should be stored in a cool, dry place as recommended on the packaging. After reconstitution, follow the storage and usage instructions provided by the manufacturer or your healthcare provider to ensure product integrity and patient safety.
Q: What is the benefit of using Trastuzumab as a targeted therapy?
A: Trastuzumab offers the advantage of specifically targeting HER2-positive cancer cells, potentially reducing damage to normal tissues and improving treatment outcomes. This targeted approach often results in better response rates and can be associated with improved survival in eligible patients.
Q: Is there any preservative in the vial of Trastuzumab For Injection?
A: No, the vial containing the lyophilized powder does not include any preservatives. However, the bacteriostatic water for injection provided as the reconstitution solvent does contain a preservative to ensure safe and efficient preparation.